Tag: Chronic lymphocytic leukemia

According to research published in 2023, several FDA-approved biosimilar versions of rituximab are considered highly similar to brand-name Rituxan and offer a safe and effective alternative for many patients. For those asking, "Is there an alternative to Rituxan?", options range from these cost-effective biosimilars to newer targeted therapies that work through entirely different mechanisms.

First approved in the U.S. in 2008, bendamustine (brand names including Treanda and Bendeka) is a potent chemotherapy agent used to treat chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphoma (NHL). As an alkylating agent, it damages the DNA of cancer cells, which ultimately leads to their destruction.

Zanubrutinib, sold under the brand name Brukinsa, is a highly selective inhibitor of Bruton's tyrosine kinase (BTK) that has been shown to offer superior efficacy and cardiac safety compared to first-generation BTK inhibitors in clinical trials. This targeted oral therapy addresses the core signaling pathways that drive the growth of malignant B-cells, representing a major advancement in the treatment of certain blood cancers. Understanding **what is the mechanism of Brukinsa** provides crucial insight into how this precision medicine combats cancer at a molecular level.